BMY - Is bluebird bio Stock a Buy?
bluebird bio (NASDAQ: BLUE) is a biotech company that specializes in gene editing, a technology that allows scientists to modify the genetic material of living organisms. Gene editing has the potential to produce life-changing therapies for conditions for which there are few (if any) treatment options. As a company that employs this technology to develop new medicines, Bluebird could deliver market-beating returns in the long run.
Further, Bluebird's stock has taken a beating of late; the company's shares are down by 36% year over year, compared with gains of 6% for the S&P 500. It could be tempting to think that Bluebird's shares must be worth buying at current levels. But before making any definitive decision, let's dive a little deeper into the company's business and figure out whether it is truly worth investing in the biotech today.